No Data
No Data
LAVA Therapeutics Analyst Ratings
H.C. Wainwright Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
Little Excitement Around LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues As Shares Take 26% Pounding
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)
JMP Securities Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
No Data